SLP Overview

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.

Wall Street analysts forecast SLP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLP is19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Simulations Plus Inc revenue for the last quarter amounts to 18.42M USD, decreased -2.66

Simulations Plus Inc. EPS for the last quarter amounts to 0.03 USD, increased 200.00

Simulations Plus Inc (SLP) has 212 emplpoyees as of March 11 2026.

Today SLP has the market capitalization of 247.00M USD.